Phase 2b trial in 243 patients with progressive fibrosing ILD despite nintedanib or pirfenidone: 26-week FVC change was -157.8 mL (pamufetinib 100 mg), -95.9 mL (50 mg) and -63.6 mL (control); pamufetinib failed to slow decline. Rash was most common.
RCTn = 243
Okuda et al. Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial